Document Detail


Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
MedLine Citation:
PMID:  15048586     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND OBJECTIVES: Peritoneal surface malignancy is a common manifestation of failure of treatment for abdominal cancers. Best results of treatment have been achieved with complete cytoreduction followed by heated intraoperative chemotherapy. Melphalan is a chemotherapeutic agent that shows increased pharmacological activity with heat. But the combination of intraperitoneal administration and heat have never been tested for this drug. The purpose of this study was to evaluate the effect of hyperthermia on the pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rodent model. METHODS: Melphalan was given by the intraperitoneal route to 20 Sprague-Dawley rats at a dose of 12 mg/kg over 90 min. Rats were randomized into two groups according to the temperature of the peritoneal perfusate: group NT received normothermic (33.5 degrees C) melphalan; group HT received hyperthermic (42 degrees C) melphalan. During the course of intraperitoneal chemotherapy, peritoneal fluid and blood were sampled at 5, 15, 30, 60 and 90 min. At the end of procedure, the rats were killed and tissues samples (heart, liver, ileum, jejunum, colon, omentum, and abdominal wall) were collected. Concentrations of melphalan were determined in peritoneal fluid, plasma, and tissues by high-performance liquid chromatography. RESULTS: The area under the curve (AUC) of peritoneal fluid melphalan was significantly lower in the HT group than in the NT group ( P=0.001), whereas no significant difference in plasma AUC was found. AUC ratios (AUC peritoneal fluid/AUC plasma) were 12.1 for the NT group and 12.3 for the HT group. The mean time to reach the plasma peak was shorter in the HT group than in the NT group ( P=0.004). The HT group exhibited increased melphalan concentrations in all intraabdominal tissues. These differences were significant for the ileum ( P=0.03) and jejunum ( P=0.04). CONCLUSION: Hyperthermia affected the pharmacokinetics of intraperitoneal melphalan by decreasing the AUC of peritoneal fluid melphalan without increasing the plasma AUC. It increased intraabdominal tissue concentrations.
Authors:
O Glehen; O A Stuart; F Mohamed; P H Sugarbaker
Related Documents :
2370566 - Monitoring of phenytoin in epileptic children: value of the single morning sample.
481656 - Changes in total body calcium on prolonged maintenance hemodialysis with high and low d...
9723826 - Constant rate infusion of vancomycin in premature neonates: a new dosage schedule.
6542606 - Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.
19265286 - Collaborative work on evaluation of ovarian toxicity. 1) effects of 2- or 4-week repeat...
11102646 - Nkp608: a selective nk-1 receptor antagonist with anxiolytic-like effects in the social...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2004-03-26
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  54     ISSN:  0344-5704     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  2004 Jul 
Date Detail:
Created Date:  2004-06-03     Completed Date:  2004-07-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  79-84     Citation Subset:  IM    
Affiliation:
Surgical Department, Centre Hospitalo-Universitaire Lyon Sud, 69495 Pierre Bénite, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents, Alkylating / administration & dosage,  pharmacokinetics*
Area Under Curve
Disease Models, Animal
Hyperthermia, Induced*
Infusions, Parenteral
Male
Melphalan / administration & dosage,  pharmacokinetics*
Peritoneal Neoplasms / drug therapy*
Rats
Rats, Sprague-Dawley
Tissue Distribution
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 148-82-3/Melphalan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differences among auxin treatments on haploid production in durum wheat x maize crosses.
Next Document:  Early aseptic loosening of cemented total hip arthroplasty: the influence of non-steroidal anti-infl...